HCC
MRK icon

Hirtle Callaghan & Co’s Merck MRK Stock Holding History

Hirtle Callaghan & Co’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,858
Closed -$294K – 97
2023
Q3 		$294K Buy
2,858
+177
+7% +$19.1K 0.01% 74
2023
Q2 		$309K Sell
2,681
-768
-22% -$87.2K 0.01% 72
2023
Q1 		$367K Buy
+3,449
New +$372K 0.02% 69
2019
Q1 		– Sell
-8,908
Closed -$649K – 110
2018
Q4 		$649K Hold
8,908
– – 0.06% 51
2018
Q3 		$603K Hold
8,908
– – 0.05% 52
2018
Q2 		$516K Hold
8,908
– – 0.05% 59
2018
Q1 		$463K Hold
8,908
– – 0.04% 64
2017
Q4 		$478K Sell
8,908
-193
-2% -$10.7K 0.04% 63
2017
Q3 		$556K Buy
9,101
+8,908
+4,616% +$540K 0.06% 52
2017
Q2 		$12K Sell
193
-46
-19% -$2.8K ﹤0.01% 161
2017
Q1 		$14K Hold
239
– – ﹤0.01% 161
2016
Q4 		$14K Sell
239
-11,702
-98% -$685K ﹤0.01% 126
2016
Q3 		$711K Buy
11,941
+2,620
+28% +$153K 0.15% 40
2016
Q2 		$512K Sell
9,321
-79
-0.8% -$4.2K 0.1% 51
2016
Q1 		$474K Buy
9,400
+8,788
+1,436% +$430K 0.09% 52
2015
Q4 		$30K Sell
612
-1,258
-67% -$63.4K 0.01% 140
2015
Q3 		$89K Hold
1,870
– – 0.02% 132
2015
Q2 		$101K Buy
+1,870
New +$105K 0.03% 137
2015
Q1 		– Sell
-26,456
Closed -$1.44M – 243
2014
Q4 		$1.44M Sell
26,456
-4,821
-15% -$269K 0.33% 48
2014
Q3 		$1.78M Sell
31,277
-282
-0.9% -$15.8K 0.29% 51
2014
Q2 		$1.75M Hold
31,559
– – 0.24% 61
2014
Q1 		$1.72M Sell
31,559
-210
-0.7% -$10.9K 0.28% 51
2013
Q4 		$1.52M Sell
31,769
-302
-0.9% -$13.8K 0.2% 58
2013
Q3 		$1.46M Buy
32,071
+30,813
+2,449% +$1.41M 0.24% 57
2013
Q2 		$56K Buy
+1,258
New +$56.2K 0.65% 33

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hirtle Callaghan & Co's MRK Position: Q4 2023 in Review

Hirtle Callaghan & Co sold out of Merck (MRK) in Q4 2023, closing a stake of 2,858 shares — an estimated $294K sold.

Hirtle Callaghan & Co first reported a position in MRK in Q2 2013 and held it in 25 quarters. The position peaked at $1.78M in Q3 2014. 3,434 funds tracked by Wall St. Rank hold MRK as of Q4 2023.

  • Hirtle Callaghan & Co reported no remaining Merck position as of Q4 2023 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 2,858 Merck shares in Q4 2023, an estimated $294K.
  • Hirtle Callaghan & Co first reported a position in Merck in Q2 2013 and held it in 25 quarters.
  • Hirtle Callaghan & Co's Merck position peaked at $1.78M in Q3 2014.
  • 3,434 funds tracked by Wall St. Rank held Merck as of Q4 2023.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2023, filed 13 Feb 2024.